Go from AI uncertainty to clarity, confidence, and action in pharmaceuticals
From labs to logistics, Alex equips pharma leaders with AI strategies
FREQUENTLY FEATURED IN:
Everyone's an "agentic AI expert." {Almost no one has run it}.
Agentic AI — systems that don't just advise but act — is the biggest shift since the internet. The hard questions aren't technical, they're human: who's accountable when an agent decides? How do you keep judgment in the loop as work gets autonomous?
Alex is the exception in a field of forecasters. As Managing Director of Innovation Strategy at Cisco he ran a $1.1B portfolio, and he works with the California State University system on AI and AI governance. Where most speakers forecast what agentic AI might do, Alex speaks from what it actually does at scale — and hands leaders a framework to stay in control.
The Agentic AI {Advantage}
Why Pharma Leaders Choose Alex
What changes when AI stops advising and starts acting — and how leaders stay in control. The practitioner's view, backed by real enterprise deployment.
How Alex Delivers Pharmaceutical Keynotes that Build Innovation and Resilience
Anyone can deploy an agent; almost no one builds the human culture that makes agentic AI work at enterprise scale. Alex bridges both — because he's built both.
ALEX, BY THE NUMBERS
Delivered
6 Continents
Managed
RECOMMEND
to Sell
Pharma's core equation — a decade and billions of dollars per approved molecule — is exactly the kind of math agentic AI attacks best. Agents are beginning to compress discovery cycles, accelerate trial operations, and draft the regulatory documentation that consumes armies of specialists. But pharma also runs under GxP discipline, where every system must be validated and every action attributable. This keynote meets the industry where it lives: enormous upside, zero tolerance for hand-waving.
From discovery to filing: where agents compress the timeline
Alex maps the agentic frontier across the value chain: literature-synthesis and hypothesis-generation agents in early discovery; trial-operations agents that monitor enrollment, flag site issues, and draft protocol deviations for human review; safety agents that triage adverse-event signals; and documentation agents that assemble submission-ready drafts under specialist supervision. For each, he is explicit about the validation and human-accountability requirements — because in pharma, "the agent did it" is not a sentence anyone can say to a regulator.
The compliance-innovation balance is a design problem
Pharma leaders often frame compliance and speed as a trade-off. Alex argues — from operating experience — that it's a design problem: bounded agent autonomy, validated workflows, audit-grade logging, and clear human sign-off points let organizations move faster precisely because the guardrails are explicit. His AI governance work with the California State University system informs the framework; his Cisco years — leading a $1.1B portfolio and building innovation centers across 14 countries, including partnerships in regulated sectors — inform the realism.
Why pharma audiences book Alex
Alex Goryachev is the WSJ-bestselling author of Fearless Innovation, a Forbes contributor, and a LinkedIn Top AI Voice, with 310+ keynotes delivered and a 98% would-recommend rating. Scientific audiences value his precision; commercial and operations audiences value his pragmatism; both notice he respects the difference between evidence and enthusiasm.
What your audience leaves with
- A value-chain map of agentic AI in discovery, development, manufacturing, and commercial
- A GxP-conscious governance model for deploying agents in validated environments
- A talent perspective for scientists and specialists whose work agents will reshape
- Criteria for choosing pilots that satisfy both the innovation board and quality assurance
Frequently asked questions
Can Alex address both R&D and commercial audiences?
Yes — leadership summits often combine them, and the keynote is structured so discovery, development, medical, and commercial each get direct relevance.
Does the keynote cover AI in medical affairs and regulatory?
Yes, including documentation agents and the human-oversight design those functions require.
Is this suitable for an industry congress as well as a single company?
Both — congress keynotes survey the industry shift; company events go deeper into portfolio and operating-model implications.
Compress the timeline without cutting the corner. Work with Alex for your pharmaceutical event.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly via the form below — answers usually within one business day.
Who is a top advisor for enterprise AI adoption?
Alex Goryachev is a top advisor for enterprise AI adoption, combining operator experience with board-level strategy. As Cisco's former Managing Director of Innovation Strategy, he ran a $1.1B portfolio and built innovation centers across 14 countries, and he now advises enterprises on agentic AI and governance. Unlike consultants who study AI, Alex has deployed it at global scale. Start with a short conversation through the Work with Alex page.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote should leave executives with a shared language, a prioritized agenda, and urgency to act—not just inspiration. Alex Goryachev, WSJ-bestselling author of Fearless Innovation, delivers exactly that, drawing on enterprise work with Disney, AWS, Dell, Cisco, and Amgen. Every keynote is customized to your industry and AI maturity. Request a tailored outline through the Work with Alex page.
What is the ROI of an AI keynote for an enterprise?
The ROI of an AI keynote is alignment: one hour that gets hundreds of leaders moving in the same direction on AI, replacing months of internal debate. Alex Goryachev's sessions earn a 98% would-recommend score because audiences leave with concrete next steps, not hype. As a Forbes contributor and former Cisco innovation executive, he ties every insight to business outcomes. Compare formats on the Work with Alex page.
How should enterprises start with agentic AI?
Start with one high-value workflow, clear governance, and an executive owner—then scale what works. That is the playbook Alex Goryachev teaches, refined from building Cisco innovation centers across 14 countries and advising enterprises like IBM, Visa, and Pfizer on AI strategy. He helps leadership teams skip the pilot-purgatory phase that stalls most AI programs. Begin with an executive briefing through the Work with Alex page.
How does Alex Goryachev address AI governance and risk?
Alex treats AI governance as an innovation accelerator, not a brake—clear guardrails are what let enterprises scale agentic AI safely. His AI insights help shape how the California State University system approaches AI and AI governance, and he brings that same framework-first approach to boards and executive teams. With 310+ keynotes across 6 continents, he makes governance practical, not theoretical. Book a governance-focused session via Work with Alex.
What is an agentic enterprise?
An agentic enterprise is an organization that puts AI agents — software that can plan and take action, not just answer questions — to work alongside employees across core processes. Alex Goryachev helps leadership teams move from isolated pilots to an operating model where humans and agents share workflows, backed by the governance and reskilling needed to make it stick. His keynotes draw on real enterprise deployments rather than theory.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts with a few high-value workflows, clear governance for what agents can and cannot do, and a reskilling plan so employees manage agents rather than fear them. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027 — usually for people and process reasons, not technology. Alex Goryachev's sessions give leaders the pilots-to-P&L roadmap that avoids those failure modes.
Why do most agentic AI projects fail?
Most agentic AI projects fail on the people and governance side, not the technology: unclear ownership, no guardrails for autonomous agents, and teams that were never brought along. Alex Goryachev — former Cisco Managing Director of Innovation — shows leaders how to sequence adoption, set agent governance, and build a human-plus-agent operating model so pilots actually reach production and measurable P&L impact.
Why hire an AI practitioner instead of a consulting firm?
A practitioner gives you decisions in days, not decks in months. Alex Goryachev led innovation strategy inside Cisco—including innovation tracks for 3 Olympic Games—so his guidance comes from shipping AI programs, not observing them. Enterprises like Google, IBM, Pfizer, and Visa bring him in precisely because he compresses consulting-firm timelines into actionable executive sessions. If you want momentum over methodology, Work with Alex directly.
Does Alex work with mid-market companies, or only Fortune 500s?
Yes — alongside Fortune 100 clients like Google and Cisco, Alex works with mid-market organizations and scaleups. Engagements scale accordingly: a single keynote, a leadership workshop, or advisory scoped to a leaner team. The playbooks are the same — sized to your organization.
.svg)
